An observational study in Glaucoma, sponsored by Clínica Rementería. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Clínica Rementería · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.
Among the 43 studies in Glaucoma with a site in Spain, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2025, is one of 10 observational ones, and was the 41st registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:
Institut Catala de Retina · Sites in Spain
Ages 50–75
Fundacio Privada Mon Clinic Barcelona · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 40–80 · Healthy volunteers
Barbara Burgos Blasco · Sites in Spain
Ages 18+
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Sites in Spain
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 100 across the 33 interventional studies, 365 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Clínica Rementería is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Clínica Rementería has 2 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, single-arm, single-center, non-randomized, non-comparative study including naïve patients attending our center diagnosed with glaucoma, who have been recommended treatment with direct selective laser trabeculoplasty (DSLT) by their ophthalmologist and who are under no hypotensive medication. DSLT treatment will be performed with the Voyager DSLT system; it will consist of the application of 120 laser pulses of preset 3 ns and a preset 400 μm spot size, with an energy of 1.8 mJ delivered to the limbus through a full 360 degrees.
The study will evaluate the effect of DSLT on intraocular pressure (IOP). Baseline IOP will be the IOP measured with Goldman applanation tonometry by the investigator on the day of treatment, prior to the application of DSLT. Patients will be seen one week (±2 days), one month (±7 days), three months (±15 days), six months (±30 days) and 12 months (±40 days) after DSLT treatment. In each of these visits, the attending ophthalmologist will measure IOP with Goldmann applanation tonometry and record the presence of any relevant ocular signs and query patients regarding potential adverse events. The study´s main end-point will be percentage reduction in IOP six months after DSLT compared to baseline.
Patients with open angle glaucoma in study eye and scheduled for both eyes being treated after bilateral laser indication.
Inclusion Criteria: • Age over 18 years
Exclusion Criteria:
Age over 18 years Diagnosis of open angle glaucoma instudy eye and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value\>21 mmHg.
Percentage change in IOP six months after DSLT compared to baseline.
Percentage change in IOP six months after DSLT compared to baseline.
Time frame: 6 months after DLST application
Percentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.
Percentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.
Time frame: 12 months
Mean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.
Mean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.
Time frame: 12 months
Proportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.
Proportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.
Time frame: 12 months
Percentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months
Percentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months
Time frame: 12 months
Mean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).
Mean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).
Time frame: 12 months
Glaucoma Quality of Life-15 Questionnaire at 12 months after DSLT.
Glaucoma Quality of Life-15 Questionnaire at 12 months after DSLT. It consists of 15 questions asking about patients difficulty for performing everyday tasks, which the patient must grade from 1 to 5, with 1 being that patient has no difficulty performing the task and 5 that he has severe diificulties. Values range from 15 (no difficulties for any activity) to 45 (has severe difficulties for performing all activities)
Time frame: 12 months
Plan to share: Yes — Age, gender, baseline IOP, severity of glaucoma, IOP at each follow-up visit, need for glaucoma medications
Supporting information: Clinical study report
Time frame: At the end of study (expected winter 2026) and for five years
Access criteria: Data deposited in a dataset repository, accessed by identified researchers
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Sep 2026, 18 months later.
Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 18 months is below that.
Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clínica Rementería